Pub Date : 2024-10-24DOI: 10.3899/jrheum.2024-0933
Robert A Colbert,Ellen Carroll,Maureen Dubreuil,Lianne S Gensler,Nigil Haroon,Richard Howard,Alexis R Ogdie,Cassie Shafer,Pamela F Weiss,Kristine A Kuhn
The Spondylitis Association of America (SAA) and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) convened a conference on the campus of the National Institutes of Health (NIH) on September 28 and 29, 2023, to identify unmet needs in spondyloarthritis (SpA) research. The conference featured presentations by experts in areas of disease endotypes, pain, innovative imaging in SpA, health disparities in rheumatic diseases, and therapeutics. Members of the conference planning committee moderated the sessions and led the development of manuscripts summarizing recommendations to address unmet research needs. Early career investigators were invited to submit abstracts, which were presented at a networking session during the conference. Here, we highlight each of the sessions comprising the conference in the form of manuscripts published together as a conference summary.
{"title":"Prologue: Spondyloarthritis Unmet Research Needs Conference IV.","authors":"Robert A Colbert,Ellen Carroll,Maureen Dubreuil,Lianne S Gensler,Nigil Haroon,Richard Howard,Alexis R Ogdie,Cassie Shafer,Pamela F Weiss,Kristine A Kuhn","doi":"10.3899/jrheum.2024-0933","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0933","url":null,"abstract":"The Spondylitis Association of America (SAA) and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) convened a conference on the campus of the National Institutes of Health (NIH) on September 28 and 29, 2023, to identify unmet needs in spondyloarthritis (SpA) research. The conference featured presentations by experts in areas of disease endotypes, pain, innovative imaging in SpA, health disparities in rheumatic diseases, and therapeutics. Members of the conference planning committee moderated the sessions and led the development of manuscripts summarizing recommendations to address unmet research needs. Early career investigators were invited to submit abstracts, which were presented at a networking session during the conference. Here, we highlight each of the sessions comprising the conference in the form of manuscripts published together as a conference summary.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-24DOI: 10.3899/jrheum.2024-0935
Kevin D Deane,Laura T Donlin,Christopher T Ritchlin,Kristine A Kuhn
Is axial spondyloarthritis (axSpA) one disease or does it comprise multiple types? If the latter, how do we define those types-through clinical or imaging features, HLA-B27 status, or by other immunologic features? Data comparing disease outcomes for individuals with nonradiographic vs radiographic axSpA, or for male vs female patients, demonstrate distinctions. So then, how should we define endotypes? Endotypes are known as the subtype of a health condition defined by a functional or pathophysiologic function. Here, we review the endotypes used for defining rheumatoid arthritis, asthma, and psoriatic arthritis. Taking the lessons learned from these diseases, we discuss how they can be applied to defining endotypes in axSpA. A key unmet need for axSpA is access to affected tissues for interrogation of their pathologic mechanisms, from which tissue-specific endotypes can be defined. These tissue-based features should be combined with clinical data and imaging to inform classification criteria in the future.
{"title":"Are There Disease Endotypes in Axial Spondyloarthritis and How Would We Define Them?","authors":"Kevin D Deane,Laura T Donlin,Christopher T Ritchlin,Kristine A Kuhn","doi":"10.3899/jrheum.2024-0935","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0935","url":null,"abstract":"Is axial spondyloarthritis (axSpA) one disease or does it comprise multiple types? If the latter, how do we define those types-through clinical or imaging features, HLA-B27 status, or by other immunologic features? Data comparing disease outcomes for individuals with nonradiographic vs radiographic axSpA, or for male vs female patients, demonstrate distinctions. So then, how should we define endotypes? Endotypes are known as the subtype of a health condition defined by a functional or pathophysiologic function. Here, we review the endotypes used for defining rheumatoid arthritis, asthma, and psoriatic arthritis. Taking the lessons learned from these diseases, we discuss how they can be applied to defining endotypes in axSpA. A key unmet need for axSpA is access to affected tissues for interrogation of their pathologic mechanisms, from which tissue-specific endotypes can be defined. These tissue-based features should be combined with clinical data and imaging to inform classification criteria in the future.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OBJECTIVEJuvenile dermatomyositis (JDM) is a rare but chronic autoimmune disease with systemic nonsuppurative inflammation. Many studies have focused on the clinical characteristics and therapy of JDM. A few studies have reported the epidemiological characteristics and social burden of JDM patients abroad, but there has been no study in China.METHODSThis study was based on the FUTang Updating medical REcords Database. Data was extracted from the registry information of inpatient medical records. The epidemiological characteristics and economic burden of Chinese JDM patients were analyzed.RESULTSA total of 1164 JDM patients from 24 hospitals were enrolled from Jan 2016 to Dec 2021. The ratio of boys to girls was 1:1.23, and half were between 6 and 12 years old. Over half(n=629) were admitted to the hospital at least twice for intensive treatment. 20% of JDM patients suffered from lung involvement and 2.2% suffered from subcutaneous calcification. The median days of hospitalization were 10 (range 6 to 14), in addition, the median United States dollar (USD) of expense was 2370.5(1373.7,3541.9). Lung involvement was the major factor causing high inpatient burden, length of stay, and expense. Nearly, 17% of JDM patients were admitted to the hospital as emergencies, suggesting sever disease activity stage needing urgent treatment. No deaths occurred in our study.CONCLUSIONOur study documents the epidemiological characteristics and social burden of JDM patients in China, contributing to the enhanced comprehension and effective management of JDM in the country.
{"title":"Epidemiological characteristics of patients with juvenile dermatomyositis in China: a multicenter study.","authors":"Xuanyi Liu,Junmei Zhang,Hui Xu,Weiying Kuang,Jianghong Deng,Xiaohua Tan,Chao Li,Shipeng Li,Yuan Xue,Guoshuang Feng,Caifeng Li,","doi":"10.3899/jrheum.2024-0003","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0003","url":null,"abstract":"OBJECTIVEJuvenile dermatomyositis (JDM) is a rare but chronic autoimmune disease with systemic nonsuppurative inflammation. Many studies have focused on the clinical characteristics and therapy of JDM. A few studies have reported the epidemiological characteristics and social burden of JDM patients abroad, but there has been no study in China.METHODSThis study was based on the FUTang Updating medical REcords Database. Data was extracted from the registry information of inpatient medical records. The epidemiological characteristics and economic burden of Chinese JDM patients were analyzed.RESULTSA total of 1164 JDM patients from 24 hospitals were enrolled from Jan 2016 to Dec 2021. The ratio of boys to girls was 1:1.23, and half were between 6 and 12 years old. Over half(n=629) were admitted to the hospital at least twice for intensive treatment. 20% of JDM patients suffered from lung involvement and 2.2% suffered from subcutaneous calcification. The median days of hospitalization were 10 (range 6 to 14), in addition, the median United States dollar (USD) of expense was 2370.5(1373.7,3541.9). Lung involvement was the major factor causing high inpatient burden, length of stay, and expense. Nearly, 17% of JDM patients were admitted to the hospital as emergencies, suggesting sever disease activity stage needing urgent treatment. No deaths occurred in our study.CONCLUSIONOur study documents the epidemiological characteristics and social burden of JDM patients in China, contributing to the enhanced comprehension and effective management of JDM in the country.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-15DOI: 10.3899/jrheum.2024-0165
Rachel E Giblon,Sara J Achenbach,Elena Myasoedova,John M Davis,Vanessa Kronzer,William V Bobo,Cynthia S Crowson
OBJECTIVETo investigate trends in depression and anxiety over three decades among individuals with rheumatoid arthritis (RA).METHODSPatients with incident RA (age >18 years, meeting 1987 ACR criteria in 1985-2014) were identified using the Rochester Epidemiology Project. Individuals with RA were matched 1:1 with non-RA comparators on age, sex, and calendar year of RA incidence. Patients were followed until death, migration or 12/31/2020. Depression and anxiety were defined using established ICD9/10 code sets. Cox models were used to compare trends in the occurrence of depression and anxiety diagnoses and cooccurring anxiety and depression by decade and RA status, adjusted for potential confounders.RESULTSThe study included 1,012 individuals with RA and 1,012 matched controls (mean age 55.9 years; 68.38% female). Hazard ratios (HR) demonstrated a temporal increase in anxiety and co-occurring anxiety and depression from 2005-2014 compared to 1985-1994 for individuals both with and without RA. Persons with RA exhibited a rising occurrence of anxiety (HR: 1.27; 95% confidence interval (CI): 0.86-1.88). and concomitant anxiety and depression (HR: 1.49; 95% CI: 0.96-2.33) compared to controls. Trends were most pronounced in seropositive RA patients (HR for anxiety: 4.01; 95% CI: 2.21-7.30).CONCLUSIONAnxiety and concomitant anxiety and depression diagnoses are elevated in individuals with RA. The increasing occurrence of anxiety and co-occurring anxiety and depression suggests rising awareness and diagnosis of these disorders. Adding to stable but high rates of depression diagnoses, individuals with RA now have evidence of a widening gap in mental health diagnoses that clinicians should address.
目的研究类风湿关节炎（RA）患者抑郁和焦虑在三十年间的变化趋势。方法通过罗切斯特流行病学项目（Rochester Epidemiology Project）确定了RA事件患者（年龄大于18岁，1985-2014年期间符合1987年ACR标准）。根据年龄、性别和 RA 发病日历年，将 RA 患者与非 RA 对照者进行 1:1 匹配。对患者进行随访，直至死亡、迁移或 2020 年 12 月 31 日。抑郁症和焦虑症使用既定的 ICD9/10 编码集进行定义。该研究纳入了 1012 名 RA 患者和 1012 名匹配对照（平均年龄 55.9 岁；68.38% 为女性）。危险比（HR）显示，与 1985-1994 年相比，2005-2014 年期间，患有和未患有 RA 的患者的焦虑症以及同时患有焦虑症和抑郁症的人数均呈上升趋势。与对照组相比，RA 患者的焦虑（HR：1.27；95% 置信区间 (CI)：0.86-1.88）和并发焦虑与抑郁（HR：1.49；95% 置信区间 (CI)：0.96-2.33）发生率呈上升趋势。在血清反应呈阳性的 RA 患者中，这一趋势最为明显（焦虑的 HR：4.01；95% CI：2.21-7.30）。焦虑以及焦虑和抑郁并发症的发生率越来越高，这表明人们对这些疾病的认识和诊断水平在不断提高。在抑郁症诊断率稳定但较高的情况下，有证据表明，RA 患者的心理健康诊断差距正在扩大，临床医生应加以解决。
{"title":"Rising? trends in Anxiety and Depression among Individuals with Rheumatoid Arthritis: A Population-Based Study.","authors":"Rachel E Giblon,Sara J Achenbach,Elena Myasoedova,John M Davis,Vanessa Kronzer,William V Bobo,Cynthia S Crowson","doi":"10.3899/jrheum.2024-0165","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0165","url":null,"abstract":"OBJECTIVETo investigate trends in depression and anxiety over three decades among individuals with rheumatoid arthritis (RA).METHODSPatients with incident RA (age >18 years, meeting 1987 ACR criteria in 1985-2014) were identified using the Rochester Epidemiology Project. Individuals with RA were matched 1:1 with non-RA comparators on age, sex, and calendar year of RA incidence. Patients were followed until death, migration or 12/31/2020. Depression and anxiety were defined using established ICD9/10 code sets. Cox models were used to compare trends in the occurrence of depression and anxiety diagnoses and cooccurring anxiety and depression by decade and RA status, adjusted for potential confounders.RESULTSThe study included 1,012 individuals with RA and 1,012 matched controls (mean age 55.9 years; 68.38% female). Hazard ratios (HR) demonstrated a temporal increase in anxiety and co-occurring anxiety and depression from 2005-2014 compared to 1985-1994 for individuals both with and without RA. Persons with RA exhibited a rising occurrence of anxiety (HR: 1.27; 95% confidence interval (CI): 0.86-1.88). and concomitant anxiety and depression (HR: 1.49; 95% CI: 0.96-2.33) compared to controls. Trends were most pronounced in seropositive RA patients (HR for anxiety: 4.01; 95% CI: 2.21-7.30).CONCLUSIONAnxiety and concomitant anxiety and depression diagnoses are elevated in individuals with RA. The increasing occurrence of anxiety and co-occurring anxiety and depression suggests rising awareness and diagnosis of these disorders. Adding to stable but high rates of depression diagnoses, individuals with RA now have evidence of a widening gap in mental health diagnoses that clinicians should address.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-15DOI: 10.3899/jrheum.2024-0608
Maria Rydholm,Sofia Hagel,Lennart T H Jacobsson,Carl Turesson
OBJECTIVETo investigate the course of disability related to the upper extremities (UE) in early rheumatoid arthritis (RA), and to assess correlations between such disability and clinical parameters, including grip force.METHODSIn an inception cohort of patients with early RA (diagnosed 1995-2005, N=222, follow-up 10 years), disability of the UE was assessed using a subscore of the Health assessment questionnaire disability index (HAQ-DI), and average grip force of the dominant hand was measured. Changes between consecutive follow-up visits in the HAQ-DI-UE subscore, and correlations at each visit with key clinical parameters, were assessed. The relation between joint involvement and HAQ-DI-UE was examined using multivariate linear regression analysis.RESULTSThe HAQ-DI-UE decreased significantly from inclusion to the 6-month follow-up (mean change -0.26; 95% CI -0.18 to -0.34), and increased significantly after 2 years. There were fairly strong correlations for HAQ-DI-UE with grip force (r:-0.50 to -0.62), patient's global assessment (r: 0.58 to 0.64) and patient's assessment of pain (r:0.54 to 0.60) at all time points through 5 years, but only moderate to weak correlations with swollen joints, CRP and ESR. At inclusion wrist synovitis and tender proximal interphalangeal (PIP) joints had both an independent impact on HAQ-DI-UE, whereas tenderness of the shoulder and the wrist had a greater importance at 6 months.CONCLUSIONDisability related to the upper extremities decreased significantly during the first 6 months, and increased again after 2 years. The correlations with clinical parameters underline the major impact of pain and impaired hand function in early RA.
{"title":"Disability Related to the Upper Extremities in Early Rheumatoid Arthritis - Long-term Course and Disease Parameter Impact: a cohort study.","authors":"Maria Rydholm,Sofia Hagel,Lennart T H Jacobsson,Carl Turesson","doi":"10.3899/jrheum.2024-0608","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0608","url":null,"abstract":"OBJECTIVETo investigate the course of disability related to the upper extremities (UE) in early rheumatoid arthritis (RA), and to assess correlations between such disability and clinical parameters, including grip force.METHODSIn an inception cohort of patients with early RA (diagnosed 1995-2005, N=222, follow-up 10 years), disability of the UE was assessed using a subscore of the Health assessment questionnaire disability index (HAQ-DI), and average grip force of the dominant hand was measured. Changes between consecutive follow-up visits in the HAQ-DI-UE subscore, and correlations at each visit with key clinical parameters, were assessed. The relation between joint involvement and HAQ-DI-UE was examined using multivariate linear regression analysis.RESULTSThe HAQ-DI-UE decreased significantly from inclusion to the 6-month follow-up (mean change -0.26; 95% CI -0.18 to -0.34), and increased significantly after 2 years. There were fairly strong correlations for HAQ-DI-UE with grip force (r:-0.50 to -0.62), patient's global assessment (r: 0.58 to 0.64) and patient's assessment of pain (r:0.54 to 0.60) at all time points through 5 years, but only moderate to weak correlations with swollen joints, CRP and ESR. At inclusion wrist synovitis and tender proximal interphalangeal (PIP) joints had both an independent impact on HAQ-DI-UE, whereas tenderness of the shoulder and the wrist had a greater importance at 6 months.CONCLUSIONDisability related to the upper extremities decreased significantly during the first 6 months, and increased again after 2 years. The correlations with clinical parameters underline the major impact of pain and impaired hand function in early RA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-15DOI: 10.3899/jrheum.2024-0881
Gretchen Santana Cepero,John E McKinnon,Kathleen Maksimowicz-McKinnon
In the article entitled "Prevalence, Predictors, and Prognosis of Serious Infections in Takayasu Arteritis: A Cohort Study" by Misra and colleagues in this issue of The Journal of Rheumatology, the authors examine the incidence of serious infections in a Takayasu arteritis (TA) patient cohort; analyze associated demographic, clinical, angiographic, and treatment-related factors; and evaluate their impact on serious infections and mortality in TA.1 They found that serious infections in patients with TA were prevalent, occurring in one-sixth of their cohort, with pneumonia (38%) and tuberculosis (TB; 24%) as the most common infections identified.1.
{"title":"Infections in Vasculitis: Can We Create an Epidemic of Change?","authors":"Gretchen Santana Cepero,John E McKinnon,Kathleen Maksimowicz-McKinnon","doi":"10.3899/jrheum.2024-0881","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0881","url":null,"abstract":"In the article entitled \"Prevalence, Predictors, and Prognosis of Serious Infections in Takayasu Arteritis: A Cohort Study\" by Misra and colleagues in this issue of The Journal of Rheumatology, the authors examine the incidence of serious infections in a Takayasu arteritis (TA) patient cohort; analyze associated demographic, clinical, angiographic, and treatment-related factors; and evaluate their impact on serious infections and mortality in TA.1 They found that serious infections in patients with TA were prevalent, occurring in one-sixth of their cohort, with pneumonia (38%) and tuberculosis (TB; 24%) as the most common infections identified.1.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-15DOI: 10.3899/jrheum.2024-0223
Victoria Navarro-Compán,Martin Rudwaleit,Maureen Dubreuil,Marina Magrey,Helena Marzo-Ortega,Philip J Mease,Jessica A Walsh,Maxime Dougados,Christine de la Loge,Carmen Fleurinck,Ute Massow,Thomas Vaux,Vanessa Taieb,Atul Deodhar
OBJECTIVETo assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).METHODSPatients were randomized to bimekizumab 160 mg or placebo every 4 weeks; and all patients received bimekizumab from week 16. Patients reported spinal pain, peripheral pain, morning stiffness, and fatigue to week 52. Total and nocturnal spinal pain were each assessed on a 0-10 numerical rating scale (NRS). Individual Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) items (0-10-point NRS) assessed peripheral arthritis pain (question [Q] 3), enthesitis pain/discomfort (Q4), morning stiffness (mean of Q5 and Q6), and fatigue (Q1). Functional Assessment of Chronic Illness Therapy Fatigue subscale score (FACIT-Fatigue) is also reported.RESULTSAt week 16, bimekizumab-treated patients reported lower mean nocturnal spinal pain, total spinal pain, and BASDAI scores (nominal except for nocturnal spinal pain; all P ≤ 0.001), as well as higher FACIT-Fatigue scores (nominal P < 0.05) vs placebo, indicating improved symptom levels. Improvements continued to week 52 in continuous bimekizumab-treated patients and in placebo-bimekizumab switchers. A higher proportion of bimekizumab- vs placebo-randomized patients achieved increasingly stringent thresholds for low spinal and peripheral pain at week 16; this was sustained or improved at week 52. Results were similar for morning stiffness and fatigue. At week 52, over half of patients were considered FACIT-Fatigue responders (≥ 8-point increase in score).CONCLUSIONBimekizumab treatment led to rapid improvements in levels of pain and morning stiffness. Substantial improvements were seen in all domains across the full disease spectrum of axSpA and continued to week 52.
目的评估在 BE MOBILE III 期研究（ClinicalTrials.gov：NCT03928704 和 NCT03928743）中，bimekizumab 对非放射性和放射性轴性脊柱关节炎 (axSpA) 患者的疼痛、晨僵和疲劳的影响。方法患者被随机分配到 bimekizumab 160 毫克或安慰剂，每 4 周一次；所有患者从第 16 周开始接受 bimekizumab 治疗。截至第52周，患者报告了脊柱疼痛、外周疼痛、晨僵和疲劳情况。总脊柱疼痛和夜间脊柱疼痛均采用 0-10 数字评分量表（NRS）进行评估。巴斯强直性脊柱炎疾病活动指数（BASDAI）的各个项目（0-10 分 NRS）评估了外周关节炎疼痛（问题 [Q] 3）、关节炎疼痛/不适（Q4）、晨僵（Q5 和 Q6 的平均值）和疲劳（Q1）。结果第16周时，与安慰剂相比，bimekizumab治疗患者的夜间脊柱疼痛、脊柱总疼痛和BASDAI平均评分较低（除夜间脊柱疼痛外均为标称值；均P≤0.001），FACIT-疲劳评分较高（标称值P＜0.05），表明症状水平有所改善。持续接受比美珠单抗治疗的患者和安慰剂-比美珠单抗转换者的症状改善持续到第52周。在第16周时，比美单抗与安慰剂随机治疗的患者中，有更高比例的患者达到了越来越严格的低脊柱和外周疼痛阈值；这种情况在第52周时得到了维持或改善。晨僵和疲劳的结果类似。第52周时，超过一半的患者被认为是FACIT-疲劳应答者（得分增加≥8分）。在axSpA的整个疾病谱中，所有领域都出现了实质性改善，并一直持续到第52周。
{"title":"Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.","authors":"Victoria Navarro-Compán,Martin Rudwaleit,Maureen Dubreuil,Marina Magrey,Helena Marzo-Ortega,Philip J Mease,Jessica A Walsh,Maxime Dougados,Christine de la Loge,Carmen Fleurinck,Ute Massow,Thomas Vaux,Vanessa Taieb,Atul Deodhar","doi":"10.3899/jrheum.2024-0223","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0223","url":null,"abstract":"OBJECTIVETo assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).METHODSPatients were randomized to bimekizumab 160 mg or placebo every 4 weeks; and all patients received bimekizumab from week 16. Patients reported spinal pain, peripheral pain, morning stiffness, and fatigue to week 52. Total and nocturnal spinal pain were each assessed on a 0-10 numerical rating scale (NRS). Individual Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) items (0-10-point NRS) assessed peripheral arthritis pain (question [Q] 3), enthesitis pain/discomfort (Q4), morning stiffness (mean of Q5 and Q6), and fatigue (Q1). Functional Assessment of Chronic Illness Therapy Fatigue subscale score (FACIT-Fatigue) is also reported.RESULTSAt week 16, bimekizumab-treated patients reported lower mean nocturnal spinal pain, total spinal pain, and BASDAI scores (nominal except for nocturnal spinal pain; all P ≤ 0.001), as well as higher FACIT-Fatigue scores (nominal P < 0.05) vs placebo, indicating improved symptom levels. Improvements continued to week 52 in continuous bimekizumab-treated patients and in placebo-bimekizumab switchers. A higher proportion of bimekizumab- vs placebo-randomized patients achieved increasingly stringent thresholds for low spinal and peripheral pain at week 16; this was sustained or improved at week 52. Results were similar for morning stiffness and fatigue. At week 52, over half of patients were considered FACIT-Fatigue responders (≥ 8-point increase in score).CONCLUSIONBimekizumab treatment led to rapid improvements in levels of pain and morning stiffness. Substantial improvements were seen in all domains across the full disease spectrum of axSpA and continued to week 52.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.3899/jrheum.2023-0698.C1
Jennifer Weinstein, S. Rosero, J. Seabury, Anika Varma, C. Engebrecht, S. Khosa, J. Heatwole, N. Dilek, Aaron Kaat, Lynne Kennedy Matallana, C. Heatwole
J Rheumatol 2024; doi: 10.3899/jrheum.2023-0698 Lynne Kennedy Matallana, MS, was missing from the author byline and footnotes. Her affiliation is National Fibromyalgia Association, Newport Beach, California, USA. She declares no conflicts of interest relevant to the article. This correction applies only to the February 15 2024 First Release. The correct author byline and footnotes appear in the print and online issues.
{"title":"Patient-Reported Impact of Symptoms in Fibromyalgia (PRISM-FM).","authors":"Jennifer Weinstein, S. Rosero, J. Seabury, Anika Varma, C. Engebrecht, S. Khosa, J. Heatwole, N. Dilek, Aaron Kaat, Lynne Kennedy Matallana, C. Heatwole","doi":"10.3899/jrheum.2023-0698.C1","DOIUrl":"https://doi.org/10.3899/jrheum.2023-0698.C1","url":null,"abstract":"J Rheumatol 2024; doi: 10.3899/jrheum.2023-0698 Lynne Kennedy Matallana, MS, was missing from the author byline and footnotes. Her affiliation is National Fibromyalgia Association, Newport Beach, California, USA. She declares no conflicts of interest relevant to the article. This correction applies only to the February 15 2024 First Release. The correct author byline and footnotes appear in the print and online issues.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"48 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140970437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2023-0981
Naomi Schlesinger, Michael H Pillinger, Peter E Lipsky
This report evaluates rheumatologists' stated adherence to and agreement with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout.
本报告评估了风湿病学家对 2020 年《美国风湿病学会（ACR）痛风管理指南》的遵守和认同情况。
{"title":"Knowledge of and stated adherence to the 2020 ACR Guideline for Gout Management: Results of a survey of US rheumatologists.","authors":"Naomi Schlesinger, Michael H Pillinger, Peter E Lipsky","doi":"10.3899/jrheum.2023-0981","DOIUrl":"https://doi.org/10.3899/jrheum.2023-0981","url":null,"abstract":"This report evaluates rheumatologists' stated adherence to and agreement with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).","authors":"Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz","doi":"10.3899/jrheum.2023-1062","DOIUrl":"https://doi.org/10.3899/jrheum.2023-1062","url":null,"abstract":"To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：